Nasdaq Biotechnology Ishares (IBB) 342.36 $IBB ISIS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 342.36 $IBB

ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST

BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32), IBB: 342.36 (-5.31), GSK: 46.73 (-0.87), ETF: 12.82 (-0.18)

IBB Doesn't Fit The Mantra Of High-Risk High-Reward
Noah Kiedrowski - at Seeking Alpha - Fri Mar 06, 2:03PM CST

IBB: 342.36 (-5.31)

Gilead, Mylan, And J&J: Cheap Compared To Peers
Hedgephone - at Seeking Alpha - Fri Mar 06, 11:32AM CST

JNJ: 100.11 (-2.41), GILD: 101.81 (-1.61), IBB: 342.36 (-5.31), MYL: 55.44 (-1.25)

Either Way - The U.S. Is In Trouble
Individual Trader - at Seeking Alpha - Thu Mar 05, 1:24AM CST

SPY: 207.50 (-2.96), IBB: 342.36 (-5.31), UUP: 25.80 (+0.31), TLT: 123.50 (-2.79)

SBIO Vs. BBC: 2 Innovative Biotech ETFs Head-To-Head - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 11:17AM CST
These newly launched products provide exposure to clinical biotechnology companies and have produced decent gains in the year-to-date frame.
SBIO: 29.86 (-0.22), BBC: 32.80 (-0.46), IBB: 342.36 (-5.31)

NASDAQ Hits 5,000: Does The IPO Market Suggest A Biotech Bubble?
Renaissance Capital IPO Research - Seeking Alpha - Tue Mar 03, 8:07AM CST
The NASDAQ Composite is fast approaching its all-time high from March 2000. On Monday it reached 5,000 for the first time since the tech bubble. Today's technology IPOs look much tamer in number than they did 15 years ago, but a boom in biotech...
QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)

In 2015, Little Is The New Big
Nicholas Vardy - Seeking Alpha - Tue Mar 03, 12:40AM CST
Editor's note: Originally published on 24 February, 2015 When it comes to stocks, “big” is sometimes little — and “little” is sometimes big. Here I’m referring here to the recent performance of small-cap stocks...
RWJ: 56.85 (-0.81), IJT: 125.46 (-1.81), IJS: 116.10 (-1.50), IJR: 114.60 (-1.60), SBB: 51.99 (+0.98), VIOO: 103.03 (-1.59), SLY: 105.10 (-1.68), SAA: 114.70 (-2.40), SDD: 38.25 (+0.76), FYX: 49.12 (-0.80), SCHA: 56.29 (-0.72), IBB: 342.36 (-5.31), ZSML: 26.49 (-0.32), VIOV: 99.91 (-1.14), SLYV: 104.52 (-1.42), RSCO: 85.80 (-1.20), RZV: 62.67 (-0.73), VB: 119.20 (-1.54), JKJ: 139.58 (-1.81), IWM: 121.17 (-1.55), VIOG: 107.25 (-1.62), SLYG: 182.09 (-2.75), RZG: 84.40 (-1.16)

Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST

JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), ACAD: 38.94 (-0.32), SPY: 207.50 (-2.96), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), ALXN: 181.65 (-4.14), IBB: 342.36 (-5.31), CELG: 118.03 (-2.68)

All That Cash
Derek Lowe - Seeking Alpha - Wed Feb 25, 1:12PM CST
From the LifeSciVC blog, here's a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that...
XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)

Manipulated Markets And How We Invest In Them
Individual Trader - at Seeking Alpha - Tue Feb 24, 6:06AM CST

SPY: 207.50 (-2.96), IBB: 342.36 (-5.31)

Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST

HEB: 0.25 (-0.01), XBI: 224.72 (-2.85), IBIO: 0.81 (-0.03), IBB: 342.36 (-5.31), SPPI: 6.26 (+0.02), CLTX: 0.91 (-0.02)

Top Funds' Activity In Q4 2014
Leo Kolivakis - Seeking Alpha - Fri Feb 20, 2:04PM CST
Svea Herbst-Bayliss and Sam Forgione of Reuters report, Top U.S. hedge funds cut Apple stakes ahead of all-time high : Top U.S. hedge fund management firms, including David Einhorn's Greenlight Capital and Philippe Laffont's Coatue Management,...
HK: 1.77 (-0.18), XLB: 50.46 (-0.69), GREK: 11.82 (-0.56), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), NBG: 1.43 (-0.08), RRC: 48.75 (-1.01), RIG: 15.52 (-0.48), XLK: 42.39 (-0.53), SPR: 49.11 (-0.52), TWTR: 46.75 (-0.60), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38), BHI: 60.92 (-1.18), XLE: 76.78 (-1.40), DVN: 59.18 (-1.65), FEYE: 42.83 (-1.08), XEC: 109.44 (-1.66), GSG: 20.44 (-0.25), NFLX: 454.12 (-13.53), GENE: 4.86 (-1.39), ROSG: 3.24 (-0.04), SBIO: 29.86 (-0.22), QQQ: 107.41 (-1.23), IDRA: 4.68 (-0.21), IWM: 121.17 (-1.55), BABA: 84.40 (-1.70)

These Stocks Are Steamrolling Everything in their Path…
Greg Guenthner - Daily Reckoning - Thu Feb 19, 8:24AM CST
This post These Stocks Are Steamrolling Everything in their Path… appeared first on Daily Reckoning . Today you’re hopping on a good ole fashioned steamroller for an honest day’s pay. Your job is to turn every underperforming industry and...
IBB: 342.36 (-5.31)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.04% Rise
Comtex SmarTrend(R) - Tue Feb 17, 4:05PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)

iShares Nasdaq Biotechnology Index Rises 1.04% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 17, 4:04PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)

Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST

PBE: 55.37 (-0.90), HQL: 28.00 (-0.26), FBT: 118.67 (-1.54), PJP: 75.85 (-1.25), XBI: 224.72 (-2.85), XPH: 123.87 (-1.47), IBB: 342.36 (-5.31), HQH: 35.27 (-0.44)

On The Cusp Of Raising Rates?
Leo Kolivakis - Seeking Alpha - Fri Feb 06, 12:59PM CST
Lucia Mutikani of Reuters reports, Strong U.S. job, wage gains open door to mid-year rate hike : U.S. job growth rose solidly in January and wages rebounded strongly, a show of underlying strength in the economy that puts a mid-year interest rate...
XLB: 50.46 (-0.69), QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), XLK: 42.39 (-0.53), IWM: 121.17 (-1.55), TWTR: 46.75 (-0.60), XLU: 43.39 (-1.34), XLV: 71.41 (-1.43), GSG: 20.44 (-0.25), XLE: 76.78 (-1.40)

Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)

Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 79

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 24

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 73

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 88

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 70

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 158

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 110

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 120

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading

Top 5 Most Recently Viewed Articles

BriteCap Financial Achieves Major Funding Milestone

Updated Category News Views 124

BriteCap Financial Achieves Major Funding Milestone BriteCap Financial, a leading small business funding platform, has proudly announced that it has surpassed $1 billion in total originations since its inception. This impressive milestone was achieved in late 2025, highlighting a year of remarkable growth and success for the company. Record Growth in 2025 The achievement...

Continue Reading
Aker Horizons ASA's Upcoming Virtual Annual Meeting Details

Updated Category News Views 261

Aker Horizons ASA Announces Details of Virtual Annual Meeting Aker Horizons ASA, a key player in green energy solutions, has scheduled its annual general meeting to take place online. This digital event will allow shareholders to engage and participate from any location, enhancing accessibility for all stakeholders. Details on the Virtual Meeting The annual general...

Continue Reading
Integrated Analytical Solutions Opens New Cannabis Lab Facility

Updated Category News Views 165

Integrated Analytical Solutions Launches a New Cannabis Testing Facility Integrated Analytical Solutions (IAS), renowned for its analytical testing services, is making strides in the cannabis industry with the grand opening of its state-of-the-art cannabis testing laboratory. This facility is a significant addition to services aimed at promoting safety, quality, and...

Continue Reading
Trip.com Group Files 2024 Annual Report with SEC Insights

Updated Category News Views 1309

Trip.com Group Limited Files Annual Report on Form 20-F Trip.com Group Limited (Nasdaq: TCOM; HKEX: 9961) has announced the submission of its annual report on Form 20-F. This report includes the company's audited financial statements covering the three years leading up to December 31, 2024, presented to the Securities and Exchange Commission. The filing was made recently...

Continue Reading
Revolutionizing Pediatric Healthcare: Office Practicum's Portal

Updated Category News Views 254

Transforming Pediatric Healthcare with an Innovative Portal Office Practicum is leading the charge in pediatric care by introducing a state-of-the-art Patient Portal, created in partnership with BridgeInteract. This comprehensive tool has been tailored specifically for pediatric practices, presenting a modern and user-friendly platform that serves both families and...

Continue Reading